{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T23:08:28Z","timestamp":1773097708461,"version":"3.50.1"},"reference-count":59,"publisher":"Oxford University Press (OUP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,1,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Motivation and method: Small-molecule inhibitors targeting the adenosine triphosphate (ATP) binding pocket of the catalytic domain of protein kinases have potential to become drugs devoid of (major) side effects, particularly if they bind selectively. Here, the sequences of the 518 human kinases are first mapped onto the structural alignment of 116 kinases of known three-dimensional structure. The multiple structure alignment is then used to encode the known strategies for developing selective inhibitors into a fingerprint. Finally, a network analysis is used to partition the kinases into clusters according to similarity of their fingerprints, i.e. physico-chemical characteristics of the residues responsible for selective binding.<\/jats:p>\n               <jats:p>Results: For each kinase the network analysis reveals the likelihood to find selective inhibitors targeting the ATP binding site. Systematic guidelines are proposed to develop selective inhibitors. Importantly, the network analysis suggests that the tyrosine kinase EphB4 has high selectivity potential, which is consistent with the selectivity profile of two novel EphB4 inhibitors.<\/jats:p>\n               <jats:p>Contact: \u00a0dhuang@bioc.uzh.ch; caflisch@bioc.uzh.ch<\/jats:p>\n               <jats:p>Supplementary information: \u00a0Supplementary data are available at Bioinformatics online.<\/jats:p>","DOI":"10.1093\/bioinformatics\/btp650","type":"journal-article","created":{"date-parts":[[2009,11,27]],"date-time":"2009-11-27T23:31:24Z","timestamp":1259364684000},"page":"198-204","source":"Crossref","is-referenced-by-count":129,"title":["Kinase selectivity potential for inhibitors targeting the ATP binding site: a network analysis"],"prefix":"10.1093","volume":"26","author":[{"given":"Danzhi","family":"Huang","sequence":"first","affiliation":[{"name":"1 Department of Biochemistry and 2 Department of Organic Chemistry, University of Z\u00fcrich, Winterthurerstrasse 190"}]},{"given":"Ting","family":"Zhou","sequence":"additional","affiliation":[{"name":"1 Department of Biochemistry and 2 Department of Organic Chemistry, University of Z\u00fcrich, Winterthurerstrasse 190"}]},{"given":"Karine","family":"Lafleur","sequence":"additional","affiliation":[{"name":"1 Department of Biochemistry and 2 Department of Organic Chemistry, University of Z\u00fcrich, Winterthurerstrasse 190"},{"name":"1 Department of Biochemistry and 2 Department of Organic Chemistry, University of Z\u00fcrich, Winterthurerstrasse 190"}]},{"given":"Cristina","family":"Nevado","sequence":"additional","affiliation":[{"name":"1 Department of Biochemistry and 2 Department of Organic Chemistry, University of Z\u00fcrich, Winterthurerstrasse 190"}]},{"given":"Amedeo","family":"Caflisch","sequence":"additional","affiliation":[{"name":"1 Department of Biochemistry and 2 Department of Organic Chemistry, University of Z\u00fcrich, Winterthurerstrasse 190"}]}],"member":"286","published-online":{"date-parts":[[2009,11,26]]},"reference":[{"key":"2023012508170106200_B1","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1042\/BJ20070797","article-title":"The selectivity of protein kinase inhibitors: a further update","volume":"408","author":"Bain","year":"2007","journal-title":"Biochem J."},{"key":"2023012508170106200_B2","doi-asserted-by":"crossref","first-page":"7898","DOI":"10.1021\/jm8011036","article-title":"Assessment of chemical coverage of kinome space and its implications for kinase drug discovery","volume":"51","author":"Bamborough","year":"2008","journal-title":"J. Med. Chem."},{"key":"2023012508170106200_B3","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1016\/j.bmcl.2008.04.015","article-title":"Inhibitors of the tyrosine kinase EphB4. Part 1: structure-based design and optimization of a series of 2,4-bis-anilinopyrimidines","volume":"18","author":"Bardelle","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"2023012508170106200_B4","doi-asserted-by":"crossref","first-page":"29618","DOI":"10.1074\/jbc.M004257200","article-title":"The replacement of ATP by the competitive inhibitor emodin induces conformational modifications in the catalytic site of protein kinase CK2","volume":"275","author":"Battistutta","year":"2000","journal-title":"J. Biol. Chem."},{"key":"2023012508170106200_B5","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1021\/jm8010542","article-title":"Kinase domain mutations in cancer: implications for small molecule drug design strategies","volume":"52","author":"Bikker","year":"2009","journal-title":"J. Med. Chem."},{"key":"2023012508170106200_B6","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.tibs.2004.01.005","article-title":"Phosphoinositide-dependent protein kinase 1, a sensor of protein conformation","volume":"29","author":"Biondi","year":"2004","journal-title":"Trends Biochem. Sci."},{"key":"2023012508170106200_B7","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/nchembio866","article-title":"Structure-guided development of affinity probes for tyrosine kinases using chemical genetics","volume":"3","author":"Blair","year":"2007","journal-title":"Nat. Chem. Biol."},{"key":"2023012508170106200_B8","doi-asserted-by":"crossref","first-page":"15435","DOI":"10.1074\/jbc.M211158200","article-title":"Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors","volume":"278","author":"Blencke","year":"2003","journal-title":"J. Biol. Chem."},{"key":"2023012508170106200_B9","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.drudis.2007.06.008","article-title":"A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding","volume":"12","author":"Bogoyevitch","year":"2007","journal-title":"Drug Discov. Today"},{"key":"2023012508170106200_B10","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/bioinformatics\/btl666","article-title":"Molecular basis for specificity in the druggable kinome: sequence-based analysis","volume":"23","author":"Chen","year":"2007","journal-title":"Bioinformatics"},{"key":"2023012508170106200_B11","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1126\/science.7909169","article-title":"Structural clues to prion replication","volume":"264","author":"Cohen","year":"1994","journal-title":"Science"},{"key":"2023012508170106200_B12","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nrd773","article-title":"Protein kinases\u2013the major drug targets of the twenty-first century?","volume":"1","author":"Cohen","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"key":"2023012508170106200_B13","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1124\/pr.55.3.4","article-title":"Specific targeted therapy of chronic myelogenous leukemia with imatinib","volume":"55","author":"Deininger","year":"2003","journal-title":"Pharmacol. Rev."},{"key":"2023012508170106200_B14","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/nrc1434","article-title":"Switching on kinases: oncogenic activation of BRAF and the PDGFR family","volume":"4","author":"Dibb","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"2023012508170106200_B15","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1074-5521(98)90170-3","article-title":"Conversion of SB 203580-insensitive MAP kinase family members to drug-sensitive forms by a single amino-acid substitution","volume":"5","author":"Eyers","year":"1998","journal-title":"Chem. Biol."},{"key":"2023012508170106200_B16","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nbt1068","article-title":"A small molecule-kinase interaction map for clinical kinase inhibitors","volume":"23","author":"Fabian","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"2023012508170106200_B17","doi-asserted-by":"crossref","first-page":"20523","DOI":"10.1073\/pnas.0708800104","article-title":"A systematic interaction map of validated kinase inhibitors with Ser\/Thr kinases","volume":"104","author":"Fedorov","year":"2007","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2023012508170106200_B18","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/nsb949","article-title":"Structural basis for p38alpha MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity","volume":"10","author":"Fitzgerald","year":"2003","journal-title":"Nat. Struct. Biol."},{"key":"2023012508170106200_B19","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/spe.4380211102","article-title":"Graph drawing by force-directed placement","volume":"21","author":"Fruchterman","year":"1991","journal-title":"Software Pract. Exper."},{"key":"2023012508170106200_B20","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/pro.5560070226","article-title":"Comprehensive assessment of automatic structural alignment against a manual standard, the scop classification of proteins","volume":"7","author":"Gerstein","year":"1998","journal-title":"Protein Sci."},{"key":"2023012508170106200_B21","doi-asserted-by":"crossref","first-page":"5065","DOI":"10.1021\/cr068221w","article-title":"Substrate and docking interactions in serine\/threonine protein kinases","volume":"107","author":"Goldsmith","year":"2007","journal-title":"Chem. Rev."},{"key":"2023012508170106200_B22","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrd2541","article-title":"High-throughput kinase profiling as a platform for drug discovery","volume":"7","author":"Goldstein","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"2023012508170106200_B23","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"2023012508170106200_B24","first-page":"519","article-title":"Managing side effects of angiogenesis inhibitors in renal cell carcinoma","volume":"30","author":"Grunwald","year":"2007","journal-title":"Onkologie"},{"key":"2023012508170106200_B25","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1096\/fasebj.9.8.7768349","article-title":"Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification","volume":"9","author":"Hanks","year":"1995","journal-title":"FASEB J."},{"key":"2023012508170106200_B26","doi-asserted-by":"crossref","first-page":"10915","DOI":"10.1073\/pnas.89.22.10915","article-title":"Amino acid substitution matrices from protein blocks","volume":"89","author":"Henikoff","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"2023012508170106200_B27","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nchembio.118","article-title":"Network pharmacology: the next paradigm in drug discovery","volume":"4","author":"Hopkins","year":"2008","journal-title":"Nat. Chem. Biol."},{"key":"2023012508170106200_B28","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1074\/jbc.M508847200","article-title":"The structure of dimeric ROCK I reveals the mechanism for ligand selectivity","volume":"281","author":"Jacobs","year":"2006","journal-title":"J. Biol. Chem."},{"key":"2023012508170106200_B29","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nbt1358","article-title":"A quantitative analysis of kinase inhibitor selectivity","volume":"26","author":"Karaman","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"2023012508170106200_B30","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.chembiol.2005.04.011","article-title":"Features of selective kinase inhibitors","volume":"12","author":"Knight","year":"2005","journal-title":"Chem. Biol."},{"key":"2023012508170106200_B31","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/prot.22028","article-title":"Structure-based tailoring of compound libraries for high-throughput screening: discovery of novel EphB4 kinase inhibitors","volume":"73","author":"Kolb","year":"2008","journal-title":"Prot. Struct. Funct. Bioinform."},{"key":"2023012508170106200_B32","doi-asserted-by":"crossref","first-page":"6433","DOI":"10.1021\/jm9009444","article-title":"Structure-based optimization of potent and selective inhibitors of the tyrosine kinase Ephb4","volume":"52","author":"Lafleur","year":"2009","journal-title":"J. Med. Chem."},{"key":"2023012508170106200_B33","first-page":"4152","article-title":"SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors","volume":"60","author":"Laird","year":"2000","journal-title":"Cancer Res."},{"key":"2023012508170106200_B34","doi-asserted-by":"crossref","first-page":"4122","DOI":"10.1021\/jm701529q","article-title":"Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of p38 MAP kinase: focus on optimized interactions with the enzyme's surface-exposed front region","volume":"51","author":"Laufer","year":"2008","journal-title":"J. Med. Chem."},{"key":"2023012508170106200_B35","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1021\/jm0608107","article-title":"Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors","volume":"50","author":"Liao","year":"2007","journal-title":"J. Med. Chem."},{"key":"2023012508170106200_B36","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1074-5521(99)80118-5","article-title":"Structural basis for selective inhibition of Src family kinases by PP1","volume":"6","author":"Liu","year":"1999","journal-title":"Chem. Biol."},{"key":"2023012508170106200_B37","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nchembio799","article-title":"Rational design of inhibitors that bind to inactive kinase conformations","volume":"2","author":"Liu","year":"2006","journal-title":"Nat. Chem. Biol."},{"key":"2023012508170106200_B38","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1126\/science.1075762","article-title":"The protein kinase complement of the human genome","volume":"298","author":"Manning","year":"2002","journal-title":"Science"},{"key":"2023012508170106200_B39","first-page":"167","article-title":"Graph drawing by force-directed placement","volume":"45","author":"Newwan","year":"2003","journal-title":"SIAM Rev."},{"key":"2023012508170106200_B40","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1126\/science.1095920","article-title":"Protein kinase inhibitors: insights into drug design from structure","volume":"303","author":"Noble","year":"2004","journal-title":"Science"},{"key":"2023012508170106200_B41","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/nsb770","article-title":"Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site","volume":"9","author":"Pargellis","year":"2002","journal-title":"Nat. Struct. Biol."},{"key":"2023012508170106200_B42","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.bmcl.2005.11.048","article-title":"Triazolo[1,5-a]pyrimidines as novel CDK2 inhibitors: protein structure-guided design and SAR","volume":"16","author":"Richardson","year":"2006","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"2023012508170106200_B43","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/nature03095","article-title":"Targeted cancer therapy","volume":"432","author":"Sawyers","year":"2004","journal-title":"Nature"},{"key":"2023012508170106200_B44","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S1074-5521(03)00159-5","article-title":"The structure of JNK3 in complex with small molecule inhibitors: structural basis for potency and selectivity","volume":"10","author":"Scapin","year":"2003","journal-title":"Chem. Biol."},{"key":"2023012508170106200_B45","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1073\/pnas.94.8.3565","article-title":"Engineering unnatural nucleotide specificity for Rous sarcoma virus tyrosine kinase to uniquely label its direct substrates","volume":"94","author":"Shah","year":"1997","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2023012508170106200_B46","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.jmb.2005.07.074","article-title":"High affinity targets of protein kinase inhibitors have similar residues at the positions energetically important for binding","volume":"352","author":"Sheinerman","year":"2005","journal-title":"J. Mol. Biol."},{"key":"2023012508170106200_B47","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1021\/jm990482t","article-title":"Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions","volume":"43","author":"Smaill","year":"2000","journal-title":"J. Med. Chem."},{"key":"2023012508170106200_B48","doi-asserted-by":"crossref","first-page":"5095","DOI":"10.1016\/j.bmcl.2005.06.083","article-title":"Design and synthesis of 6-anilinoindazoles as selective inhibitors of c-Jun N-terminal kinase-3","volume":"15","author":"Swahn","year":"2005","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"2023012508170106200_B49","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"2023012508170106200_B50","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.1093\/nar\/22.22.4673","article-title":"CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice","volume":"22","author":"Thompson","year":"1994","journal-title":"Nucleic Acids Res."},{"key":"2023012508170106200_B51","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1038\/79534","article-title":"Combinatorial chemoprevention of intestinal neoplasia","volume":"6","author":"Torrance","year":"2000","journal-title":"Nat. Med."},{"key":"2023012508170106200_B52","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0163-7258(98)00044-8","article-title":"Strategies toward the design of novel and selective protein tyrosine kinase inhibitors","volume":"82","author":"Traxler","year":"1999","journal-title":"Pharmacol. Ther."},{"key":"2023012508170106200_B53","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.bbapap.2003.11.028","article-title":"Kinomics-structural biology and chemogenomics of kinase inhibitors and targets","volume":"1697","author":"Vieth","year":"2004","journal-title":"Biochim. Biophys. Acta"},{"key":"2023012508170106200_B54","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S1359-6446(05)03477-X","article-title":"Kinomics:characterizing the therapeutically validated kinase space","volume":"10","author":"Vieth","year":"2005","journal-title":"Drug Discov. Today"},{"key":"2023012508170106200_B55","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.farmac.2004.05.010","article-title":"Sequence and structural analysis of kinase ATP pocket residues","volume":"59","author":"Vulpetti","year":"2004","journal-title":"Farmaco"},{"key":"2023012508170106200_B56","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/sj.bjc.6604497","article-title":"The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation","volume":"99","author":"Wolter","year":"2008","journal-title":"Br. J. Cancer"},{"key":"2023012508170106200_B57","doi-asserted-by":"crossref","first-page":"6652","DOI":"10.1158\/0008-5472.CAN-04-1168","article-title":"A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells","volume":"64","author":"Wood","year":"2004","journal-title":"Cancer Res."},{"key":"2023012508170106200_B58","doi-asserted-by":"crossref","first-page":"6402","DOI":"10.1021\/bi900655f","article-title":"Structural bioinformatics-based prediction of exceptional selectivity of p38 MAP kinase inhibitor PH-797804","volume":"48","author":"Xing","year":"2009","journal-title":"Biochemistry"},{"key":"2023012508170106200_B59","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jmb.2005.01.003","article-title":"Inclining the purine base binding plane in protein kinase CK2 by exchanging the flanking side-chains generates a preference for ATP as a cosubstrate","volume":"347","author":"Yde","year":"2005","journal-title":"J. Mol. Biol."}],"container-title":["Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bioinformatics\/article-pdf\/26\/2\/198\/48855202\/bioinformatics_26_2_198.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bioinformatics\/article-pdf\/26\/2\/198\/48855202\/bioinformatics_26_2_198.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T08:17:54Z","timestamp":1674634674000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bioinformatics\/article\/26\/2\/198\/210180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11,26]]},"references-count":59,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,1,15]]}},"URL":"https:\/\/doi.org\/10.1093\/bioinformatics\/btp650","relation":{},"ISSN":["1367-4811","1367-4803"],"issn-type":[{"value":"1367-4811","type":"electronic"},{"value":"1367-4803","type":"print"}],"subject":[],"published-other":{"date-parts":[[2010,1,15]]},"published":{"date-parts":[[2009,11,26]]}}}